What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Surgery
Christopher P. Cannon focuses on Internal medicine, Myocardial infarction, Cardiology, TIMI and Surgery.
Acute coronary syndrome, Coronary artery disease, Clopidogrel, Percutaneous coronary intervention and Heart failure are among the areas of Internal medicine where the researcher is concentrating his efforts.
His Myocardial infarction research incorporates themes from Stroke, Atorvastatin and Hazard ratio.
His Cardiology study combines topics from a wide range of disciplines, such as Odds ratio and Platelet aggregation inhibitor.
His studies in TIMI integrate themes in fields like Fibrinolytic agent, Sibrafiban and C-reactive protein.
His Surgery research is multidisciplinary, relying on both Placebo and Kidney disease.
His most cited work include:
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes (4782 citations)
- Intensive versus moderate lipid lowering with statins after acute coronary syndromes. (3936 citations)
- C-Reactive Protein Levels and Outcomes after Statin Therapy (1905 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Cardiology, Myocardial infarction, TIMI and Acute coronary syndrome.
His study on Clopidogrel, Unstable angina, Percutaneous coronary intervention and Coronary artery disease is often connected to In patient as part of broader study in Internal medicine.
The concepts of his Cardiology study are interwoven with issues in Odds ratio and Aspirin.
His Myocardial infarction study incorporates themes from Stroke, Surgery and Hazard ratio.
Christopher P. Cannon interconnects Fibrinolysis and Risk factor in the investigation of issues within TIMI.
His biological study deals with issues like Atorvastatin, which deal with fields such as Statin.
He most often published in these fields:
- Internal medicine (77.75%)
- Cardiology (56.18%)
- Myocardial infarction (43.67%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (77.75%)
- Cardiology (56.18%)
- In patient (12.06%)
In recent papers he was focusing on the following fields of study:
Christopher P. Cannon mostly deals with Internal medicine, Cardiology, In patient, Myocardial infarction and Diabetes mellitus.
Internal medicine is a component of his Acute coronary syndrome, Atrial fibrillation, Percutaneous coronary intervention, Heart failure and Conventional PCI studies.
Christopher P. Cannon usually deals with Acute coronary syndrome and limits it to topics linked to Ezetimibe and Placebo.
His research in Percutaneous coronary intervention intersects with topics in Regimen and Aspirin.
His Cardiology research includes themes of Atherosclerotic cardiovascular disease and PCSK9.
His study in Myocardial infarction is interdisciplinary in nature, drawing from both Stroke, Interquartile range, Randomized controlled trial and Hazard ratio.
Between 2017 and 2021, his most popular works were:
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (1296 citations)
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (1296 citations)
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (219 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Myocardial infarction
Internal medicine, Diabetes mellitus, Acute coronary syndrome, Myocardial infarction and Cardiology are his primary areas of study.
His studies deal with areas such as Type 2 diabetes and Type 2 Diabetes Mellitus as well as Internal medicine.
Christopher P. Cannon combines subjects such as Clinical trial, MEDLINE, Kidney disease, Randomized controlled trial and Blood pressure with his study of Diabetes mellitus.
His study in Acute coronary syndrome is interdisciplinary in nature, drawing from both Coronary artery disease, Ezetimibe, Clinical endpoint, Metabolic syndrome and Clopidogrel.
His studies deal with areas such as Young adult, Interquartile range and Cohort as well as Myocardial infarction.
His research on Cardiology focuses in particular on Heart failure.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
